Vitamin E
Vitamin E has been studied in 386 papers since 1980: 35 trials and 145 observational studies in people, 52 in animals, 7 in cells, 143 reviews; 96 in the past year. The newest paper, Nov 19, 2026: “Protective effects of intermittent fasting and vitamin E against hyperthyroidism-associated ocular complications in Wistar rats”.
Research on it is growing about as fast as aging research as a whole: 18 papers in the latest year counted
15 new papers in 30 daysSee all 573 papers on vitamin E
At a glance
Independent labs found the same change in worms or flies, mice and people. 106 independent labs in 25 countries; 119 trials, 4 about aging, 68 with no results posted.
“yielded hazard ratios of 0.88 (95% CI, 0.64-1.20) for vitamin E, 0.83 (0.60-1.13) for selenium, and 1.00 (0.75-1.35) for the combination compared with placebo”
28 of its findings point the other way.
- 106 independent labs in 25 countries
- 28 findings against
- 119 trials, 4 about aging, 68 with no results posted
- Funders: National Institutes of Health and others
- 11 of 208 findings with company ties
- Human trial35
- Humans145
- Animals47
- Model organisms5
- Cells7
- In silico3
Studies in people
See all 11 studies of vitamin E in people11 studies gave vitamin E to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on japanese knee osteoarthritis measure score no change: Has no effect on physical function down: Decreases inflammatory markers | Randomized trial24 weeks | 80 peopleWomen71.9 ± 5.6 yearsOlder adults; Postmenopausal women; Postmenopausal women with symptomatic knee osteoarthritis | Medicine, Oct 16, 2026 |
down: Decreases LDL-C | Randomized trial | 90 peopleGeneral population; in healthy volunteers | Nutrition, metabolism, and cardiovascular diseases : NMCD, Feb 25, 2025 |
down: Decreases hot flashesnearly one-third of the base amount, P = 0.002 down: Decreases triglycerideP < 0.001 down: Decreases aspartate aminotransferaseP = 0.007 | Randomized trialeight weeks | 84 peopleWomenPostmenopausal women | Health care for women international, Sep 2, 2022 |
down: Decreases CTX-0.003 ± 0.09 versus 0.121 ± 0.15 with placebo | Randomized trial12 weeks | 52 peopleWomenPostmenopausal women; Postmenopausal osteopenic women | Nutrients, Nov 25, 2021 |
down: Decreases hot flashesadjusted mean difference -8.7, 95% CI -0.6 to -15.0, P = 0.029 no change: Has no effect on anxietyP > 0.05 | Randomized trial8 weeks | 93 peopleWomen51.7 yearsPostmenopausal women; postmenopausal hot flashes | Complementary therapies in medicine, Nov 26, 2019 |
What did lifespan studies of vitamin E find?
DrugAgeDrugAge records 30 results from 12 papers: 10 in Z. paravittiger, 9 in C. elegans, 4 in P. tetraurelia and 4 other species. Average lifespan is the mean or the median, as each paper reports it.
- Z. paravittigermales, 1 μg/mL+2.2% average+8.8% maximum
- C. elegansN2, 200 µg/mL+20.6% average0% maximum
- P. tetraurelia10 mg/L−6.8% averagenot significant
- A. brightwelliclone 4B61, 3 mM+16.4% average+6.7% maximum
- D. melanogasterCanton S, females, 100 µg/ml+2% average
- M. domesticamales, 0.50%−9.2% averagenot significant
What did studies of vitamin E find?
89Studies of vitamin E measured 89 outcomes; the most studied are lifespan (12 studies), oxidative stress and ROS signaling (8) and cognitive function (5).
Lifespan
upin mice5no changein mice4upin worms3no changein T. commodus1+17%
12 studies
Lifespan
upin mice5no changein mice4upin worms3no changein T. commodus1+17%
Vitamin E extends lifespan in worms (gpx-quad mutant background).
Model organismsgpx-quad mutant background
Vitamin E extends lifespan in worms (gas-1(fc21) mitochondrial complex I disease model).
Model organismsgas-1(fc21) mitochondrial complex I disease model
Vitamin E showed no clear effect on lifespan in T. commodus.
Model organismsDL-alpha-tocopherol
Vitamin E extends lifespan in MRL/lpr mice.
Animalsin MRL/lpr mice250 mg/kg vs 500 mg/kgfemales
Vitamin E extends lifespan in mice (+17%).
Animals5.0 g alpha-tocopherol acetate/kg of foodmales
Vitamin E extends lifespan in mice (+40% (61 +/- 4 wk to 85 +/- 4 wk)).
Animals5.0 g alpha-tocopherol acetate/kg of foodmales
Vitamin E extends lifespan in female NZB/W F1 mice fed oxidised frying oil.
Animalsin female NZB/W F1 mice fed oxidised frying oilall-rac-alpha-tocopheryl acetate550 mg/kg dietfemales
Vitamin E extends lifespan in worms (wild-type).
Model organismswild-type
Vitamin E extends lifespan in mice (+25-20% (median and maximal)).
Reviewmales
Vitamin E showed no clear effect on lifespan in mice (median lifespans: 804, 830 and 801 days).
Animalsdietthroughout life, from the time of conception until death
All 14Fewer
Oxidative stress and ROS signaling
downin mice4downin E. caballus1no changein mice1downin rats1+1
8 studies
Oxidative stress and ROS signaling
downin mice4downin E. caballus1no changein mice1downin rats1+1
Vitamin E decreases oxidative stress and ROS signaling in rats (lithium-treated aged rats).
Animalslithium-treated aged ratsliver100 mg/kg every other dayfour weeksn = 48
Vitamin E decreases oxidative stress and ROS signaling in mice (higher doses showed greater effects).
Animalshigher doses showed greater effects100, 200, or 400 mg/kg28 daysmales
Vitamin E decreases oxidative stress and ROS signaling in mice.
Animalsheart and brain100, 200, and 400 mg/kg28 days
Vitamin E decreases oxidative stress and ROS signaling.
Review
Vitamin E decreases oxidative stress and ROS signaling in mice.
Animalsantioxidant supplementationbrown adipose tissue
Vitamin E decreases oxidative stress and ROS signaling in E. caballus (exercise-induced oxidative stress).
Reviewexercise-induced oxidative stress
Vitamin E decreases oxidative stress and ROS signaling in mice.
Reviewbrain
Vitamin E showed no clear effect on oxidative stress and ROS signaling in mice.
Animalsheart1.65 g/kg13 weeks
Cognitive function
no changein humans4mediatesin humans1
5 studies
Cognitive function
no changein humans4mediatesin humans1
Vitamin E showed no clear effect on cognitive function in humans.
Human trial3 months
Vitamin E showed no clear effect on cognitive function in humans (Down syndrome).
Human trialDown syndromeoral1,000 IU twice daily3 yearsn = 337
Vitamin E was not clearly linked with cognitive function in humans (r = 0.027, p = 0.806).
Humansn = 85
Vitamin E is linked with cognitive function in humans (dietary fiber-cognitive function association) (85.0% mediation).
Humansdietary fiber-cognitive function associationn = 2,713
Vitamin E showed no clear effect on cognitive function in humans (Non-demented adults).
ReviewNon-demented adults≥3 months
Mortality
no changein humans2upin rats1downin reviews1
4 studies
Mortality
no changein humans2upin rats1downin reviews1
Vitamin E showed no clear effect on mortality in humans (Down syndrome) (p = 0.086).
Human trialDown syndromeoral1,000 IU twice daily3 yearsn = 337
Vitamin E was not clearly linked with mortality in current smokers.
Humansin current smokersmedian follow-up of 119.7 months
Vitamin E decreases mortality.
Review
Vitamin E increases mortality in rats (streptozocin-induced diabetes) (84% died by 6 mo).
Animalsstreptozocin-induced diabetes100 IU vitamin E/kg chow6 momales
Triglyceride
downin humans2
2 studies
Triglyceride
downin humans2
Vitamin E decreases triglyceride in humans (P < 0.001).
Human trialcapsules200 IU twice/dailyeight weeksfemales
Vitamin E is linked with lower triglyceride in Brazilian (ISA) and U.S. Hispanic/Latino (NHANES) participants.
Humansin Brazilian (ISA) and U.S. Hispanic/Latino (NHANES) participants
Inflammation
downin humans1downin reviews1
2 studies
Inflammation
downin humans1downin reviews1
Vitamin E is linked with lower inflammation in humans (P < .05).
Humans
Vitamin E decreases inflammation.
Review
Liver fibrosis
downin humans1downin rats1
2 studies
Liver fibrosis
downin humans1downin rats1
Vitamin E decreases liver fibrosis in rats (lithium toxicity).
Animalslithium toxicityliver100 mg/kg every other dayfour weeksn = 48
Vitamin E decreases liver fibrosis in humans (obesity-linked liver disease).
Reviewobesity-linked liver disease
LDL-C
downin humans1upin rats1
2 studies
LDL-C
downin humans1upin rats1
Vitamin E decreases LDL-C in healthy volunteers.
Human trialin healthy volunteersn = 90
Vitamin E increases LDL-C in the CV group.
Animalsin the CV groupliver
SIRT1
upin mice2
2 studies
SIRT1
upin mice2
Vitamin E increases SIRT1 in mice (particularly at higher doses).
Animalsparticularly at higher doses100, 200, or 400 mg/kg28 daysmales
Vitamin E increases SIRT1 in mice (gene expression measured in heart and hippocampus).
Animalsgene expression measured in heart and hippocampusheart and hippocampus100, 200, and 400 mg/kg28 days
Hot flashes
downin humans2
2 studies
Hot flashes
downin humans2
Vitamin E decreases hot flashes in humans (nearly one-third of the base amount, P = 0.002).
Human trialcapsules200 IU twice/dailyeight weeksfemales
Vitamin E decreases hot flashes in humans (postmenopausal hot flashes) (adjusted mean difference -8.7, 95% CI -0.6 to -15.0, P = 0.029).
Human trialpostmenopausal hot flashestablets200 IU/day8 weeksfemalesn = 93
Dementia
no changein humans2HR 0.88
2 studies
Dementia
no changein humans2HR 0.88
Vitamin E showed no clear effect on dementia in humans (compared with placebo; Cox model adjusted for demographics and baseline comorbidities) (HR 0.88 (95% CI 0.64-1.20)).
Human trialcompared with placebo; Cox model adjusted for demographics and baseline comorbiditiesmalesn = 7,338
Vitamin E showed no clear effect on dementia in humans (Down syndrome) (11%/year).
Human trialDown syndromeoral1,000 IU twice daily3 yearsn = 337
NAFLD Activity Score
downin humans1
1 study
NAFLD Activity Score
downin humans1
Vitamin E decreases NAFLD Activity Score in humans (change in mean score, −1.8 vs −0.7).
Human trial96 weeks
Vitamin E decreases NAFLD Activity Score in humans (pediatric NAFLD) (-1.8 vs -0.7, P = .02).
Human trialpediatric NAFLD800 IU daily96 weeksn = 58
Metabolic dysfunction-associated steatohepatitis
downin humans1
1 study
Metabolic dysfunction-associated steatohepatitis
downin humans1
Vitamin E decreases metabolic dysfunction-associated steatohepatitis in humans (58% vs 28%).
Human trial96 weeksn = 121
Vitamin E decreases metabolic dysfunction-associated steatohepatitis in humans (pediatric NASH) (58% vs 28%, P = .006).
Human trialpediatric NASH800 IU daily96 weeksn = 43
Alanine aminotransferase
no changein humans1
1 study
Alanine aminotransferase
no changein humans1
Vitamin E showed no clear effect on alanine aminotransferase in humans (26% vs 17%).
Human trial96 weeks
Vitamin E showed no clear effect on alanine aminotransferase in humans (pediatric NAFLD) (26% vs 17%, P = .26).
Human trialpediatric NAFLD800 IU daily96 weeksn = 58
Inflammatory markers
downin humans1
1 study
Inflammatory markers
downin humans1
Vitamin E decreases inflammatory markers in humans.
Human trialWithin-group change during vitamin E plus home exercise; no significant between-group difference24 weeksfemales
All 89Fewer
What is vitamin E linked with?
58Studies link vitamin E with 58 measures, most often cognitive impairment (4 studies), mortality (3) and telomere length (3).
Cognitive impairment
downin humans4OR 0.94
4 studies
Cognitive impairment
downin humans4OR 0.94
Vitamin E is associated with cognitive impairment in humans.
Humans
Vitamin E is linked with a lower risk of cognitive impairment in humans (OR = 0.94, 95% CI 0.91-0.97).
Humansn = 2,255
Vitamin E is linked with a lower risk of cognitive impairment in humans.
Humans
Vitamin E is associated with cognitive impairment in humans.
Reviewdietary component or multivitamin supplement
Mortality
downin humans3HR 0.68
3 studies
Mortality
downin humans3HR 0.68
Vitamin E is linked with a lower risk of mortality in former smokers and non-smokers.
Humansin former smokers and non-smokersmedian follow-up of 119.7 months
Vitamin E is associated with mortality in humans (US NHANES cohort; multivariable-adjusted association) (32% lower mortality risk; HR 0.68, 95% CI 0.55-0.84).
HumansUS NHANES cohort; multivariable-adjusted associationhighest versus lowest tertilen = 12,977
Vitamin E is linked with a lower risk of mortality in humans (fully adjusted model) (Q4: 0.77 [0.63, 0.94]).
Humansfully adjusted model
Telomere length
mixedin humans1downin humans1upin humans1
3 studies
Telomere length
mixedin humans1downin humans1upin humans1
Vitamin E is associated with telomere length in humans.
Humansn = 10,793
Vitamin E is associated with telomere length in humans (established cardiovascular disease; inadequate versus adequate vitamin E intake) (Shorter LTL with inadequate intake; p = .004, .015, and .005 across three dietary recommendations).
Humansestablished cardiovascular disease; inadequate versus adequate vitamin E intakeleukocyten = 1,002
Vitamin E is associated with telomere length in humans.
Humansfrom foodsleukocyte DNAfemalesn = 586
Sarcopenia
downin humans3OR 0.14
3 studies
Sarcopenia
downin humans3OR 0.14
Vitamin E is linked with a lower risk of sarcopenia in humans (NHANES 2011-2018).
HumansNHANES 2011-2018n = 9,436
Vitamin E is associated with sarcopenia in humans (subcomponent analysis of CDAI).
Humanssubcomponent analysis of CDAI
Vitamin E is linked with a lower risk of sarcopenia in humans (highest vs lowest quantile) (OR 0.14, CI 0.04-0.49).
Humanshighest vs lowest quantilen = 1,345
Chronic kidney disease
downin humans2OR 0.5–0.869
2 studies
Chronic kidney disease
downin humans2OR 0.5–0.869
Vitamin E is associated with chronic kidney disease in humans (Simultaneous adjustment for total energy, protein, sodium, potassium, and phosphorus) (OR 0.869, 95% CI 0.768–0.982).
HumansSimultaneous adjustment for total energy, protein, sodium, potassium, and phosphorusn = 8,676
Vitamin E is associated with chronic kidney disease in humans (OR 0.50, 95% CI: 0.43–0.80).
Humans
Cognitive function
downin humans2OR 0.73
2 studies
Cognitive function
downin humans2OR 0.73
Vitamin E is associated with cognitive function in multivariate models.
Humansin multivariate modelsn = 5,591
Vitamin E is linked with a lower risk of cognitive function in humans (elevated dietary intake) (OR = 0.73, 95% CI: 0.56-0.94).
Humanselevated dietary intake
Age-related macular degeneration
downin humans2
2 studies
Age-related macular degeneration
downin humans2
Vitamin E is associated with age-related macular degeneration in humans.
Humans
Vitamin E lowers the risk of age-related macular degeneration in humans.
Review
Metabolic syndrome
downin humans1mixedin humans1
2 studies
Metabolic syndrome
downin humans1mixedin humans1
Vitamin E is linked with a lower risk of metabolic syndrome in U.S. Hispanic/Latino participants (NHANES).
Humansin U.S. Hispanic/Latino participants (NHANES)
Vitamin E is associated with metabolic syndrome in humans (P < .01).
Humans
Prostate cancer
upin humans1downin humans1
2 studies
Prostate cancer
upin humans1downin humans1
Vitamin E raises the risk of prostate cancer in men.
Reviewin men
Vitamin E lowers the risk of prostate cancer in high-risk groups like smokers.
Reviewin high-risk groups like smokers
Osteoporosis
downin humans2OR 0.652–0.96
2 studies
Osteoporosis
downin humans2OR 0.652–0.96
Vitamin E is linked with a lower risk of osteoporosis in humans (OR 0.96, 95% CI 0.93-0.98).
Humansn = 5,800
Vitamin E is linked with a lower risk of osteoporosis in humans (Q4 vs first quartile) (OR 0.652; 95% CI 0.463-0.918).
HumansQ4 vs first quartilen = 5,618
All 58Fewer
Has vitamin E been tested in people?
4 of 119 about agingYes: 35 trials and 145 observational studies in people have been published, and 119 trials are registered.
About aging
Completed
Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.
Phase 3Completed
Phase 3Completed
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Phase 3Completed
Every condition in trials
Metabolic dysfunction-associated steatotic liver disease
Phase 4Results posted7 trials
Phase 4Results posted7 trials
Phase 4Results posted5 trials
Phase 4Completed4 trials
Phase 4Completed3 trials
Phase 4Terminated2 trials
40 of 147Fewer
Readouts due
- Dec 8, 2026
- Jan 30, 2027
- Mar 30, 2027
Stopped
NCT00809458TerminatedProstatic neoplasm
Low rate of accrual.
NCT00515736TerminatedCritical illness
enrollment was completed
NCT00740714TerminatedParkinson's disease
The investigational drug is unlikely to demonstrate efficacy over placebo for this indication. However, no safety issues were discovered.
NCT00152841TerminatedCrohn's disease
Lack of patients
NCT01897792TerminatedHealthcare-associated pneumonia
Inability to recruit patients that meet inclusion criteria.
NCT02758990TerminatedAnxiety
Recruiting and financial constraints
All 7Fewer
Who is developing vitamin E?
1 company: BREGO Life Sciences.
- Companies
- BREGO Life Sciencesdiabetic foot ulcer, diabetic symmetrical polyneuropathy
Trial sponsors
Company1 trial100 people
Company1 trial16 people
4 trialsPhase 4210 people
2 trialsPhase 41,490 people
Seoul National University Hospital
1 trialPhase 4320 people
VA Office of Research and Development
1 trialPhase 4105 people
1 trialPhase 4100 people
Sir Takhtasinhji General Hospital
1 trialPhase 495 people
Funding
3 grants since 2018National Institute of Neurological Disorders and Stroke$1.4MJapan Society for the Promotion of Science¥4.3MNational Institute of Allergy and Infectious Diseases$20.1K
Japan Society for the Promotion of ScienceKanagawa Institute of Technology¥4.3M2026–2029
Tocotrienol Vitamin E Against Stroke
National Institute of Neurological Disorders and StrokeIndiana University Indianapolis$345K2002–2023
National Institute of Allergy and Infectious DiseasesTufts University Boston$20.1K2016–2018